Visual Abstract Summary for the ARIES-HM3 Trial Question Can aspirin be safely excluded from an antithrombotic regimen, including a vitamin K antagonist (VKA), in patients with a fully magnetically levitated LVAD, and does this reduce nonsurgical bleeding complications? Design Key … Read More
heart failure
ATHENA-HF Trial: High-Dose Spironolactone in Acute Heart Failure
The ATHENA-HF trial, published in JAMA Cardiology in 2017, evaluated the efficacy and safety of high-dose spironolactone in patients with acute heart failure (AHF). This was a double-blind, placebo-controlled randomized clinical trial, aiming to assess whether high-dose spironolactone could significantly … Read More
TRISCEND II Trial: Transcatheter Tricuspid Valve Replacement in Severe TR
TRISCEND II Trial: EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) Severe tricuspid regurgitation (TR) has historically been challenging to treat, with medical therapy offering limited relief. The TRISCEND II trial (2024) marks a significant milestone by assessing the safety and efficacy … Read More
Landmark Clinical Trials of Aldosterone Antagonists
landmark clinical trials focusing on aldosterone antagonists (mineralocorticoid receptor antagonists) like spironolactone and eplerenone, which are commonly used in heart failure and other conditions: 1. RALES (1999) • Title: Randomized Aldactone Evaluation Study • Focus: Heart failure with reduced ejection … Read More
IRONMAN Trial: IV Iron in HF
IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
DEA-HF Trial: Diuretics Regimen in CHF
The infographic details findings from the DEA-HF study, which was designed to evaluate the efficacy and safety of three different diuretic treatment regimens in patients with ambulatory congested heart failure (CHF). The study was conducted in a prospective, randomized, open-label, … Read More
REDUCE LAP-HF II: Atrial Shunt Device in HFpEF and HFmEF
Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More
DAPA-MI Trial: Dapagliflozin in MI
DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
HEART-FID Trial: Iron in Heart Failure
The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More